Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Clinical Oncology

• Publication date

  2013-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2012.43.5966PMID 23248257PMCID PMC4878037
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Author response: Registered report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

  2015cited by this paper
• Improved survival with MEK inhibition in BRAF-mutated melanoma.

  2012cited by this paper
• Management of immune-related adverse events and kinetics of response with ipilimumab.

  2012cited by this paper
• Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

  2012cited by this paper
• NRAS mutation status is an independent prognostic factor in metastatic melanoma

  2012cited by this paper
• Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma.

  2012cited by this paper
• Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

  2012cited by this paper
• Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

  2012cited by this paper
• Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

  2012cited by this paper
• Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

  2012cited by this paper
• Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

  2011cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

  2011influential reference
• Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation-positive metastatic melanoma patients (pts).

  2011cited by this paper
• Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway

  2011cited by this paper
• Morphologic and immunohistochemical (IHC) changes in metastatic melanoma (MM) tissue and associations with clinical outcome in patients (pts) on BRAF inhibitors (BRAFi).

  2011cited by this paper
• Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

  2011cited by this paper
• Frequency of mutations associated with targeted therapy in malignant melanoma patients.

  2011cited by this paper
• Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma.

  2011cited by this paper
• Inhibition of mutated, activated BRAF in metastatic melanoma.

  2010cited by this paper
• Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

  2010cited by this paper
• A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer

  2010cited by this paper
• Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers

  2010cited by this paper
• Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.

  2010cited by this paper
• COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation

  2010cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

  2008cited by this paper
• Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.

  2008cited by this paper
• Number of Nevi and Early-Life Ambient UV Exposure Are Associated with BRAF-Mutant Melanoma

  2007cited by this paper
• Distinct sets of genetic alterations in melanoma.

  2005cited by this paper
• Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.

  2005cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• Planned versus attained design in phase II clinical trials.

  1992cited by this paper

• Therapeutic Potential of Tyrosine Kinase Inhibitors in Advanced Thyroid Cancer

  2026cites this paper
• Dissecting the MAPK signaling landscape in malignant melanoma: from BRAF and NRAS mutations to precision combination therapies

  2026cites this paper
• The MEK–RAF molecular glue IK-595 has potent antitumor activity across RAS/MAPK pathway-altered cancers

  2026cites this paper
• Developments of MEK inhibitors as future cancer therapies: what have we learned from preclinical and clinical studies?

  2025cites this paper
• The Hidden Hand of Endoplasmic Reticulum Stress in Anticancer Drug Resistance.

  2025cites this paper
• JAK and MEK Pathways as Therapeutic Targets for Saphenous Vein Smooth Muscle Cell Dysfunction in Type 2 Diabetes via Regulation of Mitochondrial Activity

  2025cites this paper
• Tumor response and thyroglobulin change in differentiated thyroid carcinoma treated with dabrafenib plus trametinib

  2025cites this paper
• Molecular regulation by ubiquitin-specific proteases (USPs) in HCC: cell cycle, oncogenic signaling, and beyond

  2025cites this paper
• Targeted therapy in pediatric central nervous system tumors: a review from the National Pediatric Cancer Foundation

  2025cites this paper
• Fyn inhibition by TAE684: A synergistic strategy to suppress melanoma and reverse vemurafenib resistance

  2025cites this paper
• Cutaneous adverse events of pan-RAF inhibitor naporafenib (LXH254) containing drug combinations in NRAS-mutant metastatic melanoma

  2025cites this paper
• Trametinib thwarts activation of survival pathways induced by pro-ferroptotic drug conjugate ACXT-3102 resulting in enhanced pancreatic cancer cell death.

  2025cites this paper
• Trends of adverse event reports associated with BRAF and MEK inhibitors and combinations: a retrospective disproportionality analysis using the FDA adverse event reporting system database from 2012 to 2021.

  2025cites this paper
• Pathway-Specific Therapeutic Modulation of Melanoma: Small-Molecule Inhibition of BRAF–MEK and KIT Signaling in Contemporary Precision Oncology with a Special Focus on Vemurafenib, Trametinib, and Imatinib

  2025cites this paper
• Senescent Fibroblasts Drive Melanoma Progression Through GCP‐2 Induced CREB Phosphorylation Enhancing Glycolysis

  2025cites this paper
• Treatment-Related Adverse Events in Individuals with BRAF-Mutant Cutaneous Melanoma Treated with BRAF and MEK Inhibitors: A Systematic Review and Meta-Analysis

  2025cites this paper
• Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer

  2024cites this paper
• Harnessing the role of aberrant cell signaling pathways in glioblastoma multiforme: a prospect towards the targeted therapy

  2024cites this paper
• Incorporating Real Option Value in Valuing Innovation: A Way Forward

  2024cites this paper
• Population Pharmacokinetics, Pharmacodynamics and Safety Properties of Trametinib in Dogs With Cancer: A Phase I Dose Escalating Clinical Trial.

  2024cites this paper
• Combination of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600E-Mutated Thyroid Cancer

  2024cites this paper
• Predicting Tumor Volume Doubling Time and Progression-Free Survival in Untreated Patients from Patient-Derived-Xenograft (PDX) Models: A Translational Model-Based Approach

  2024cites this paper
• Precision Oncology in Melanoma and Skin Cancer Surgery.

  2024cites this paper
• Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP

  2024cites this paper
• Efficacy of trametinib in a metastatic urothelial carcinoma patient with a BRAF mutation

  2024cites this paper
• Mucocutaneous toxicities from MEK inhibitors: a scoping review of the literature

  2024cites this paper
• Emerging Targeted Therapies and Strategies to Overcome Resistance in Biliary Tract Cancers.

  2024cites this paper
• Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology – an analysis of the closed cohorts of a multicentre prospective study

  2024cites this paper
• Population Pharmacokinetics of Trametinib and Impact of Nonadherence on Drug Exposure in Oncology Patients as Part of the Optimizing Oral Targeted Anticancer Therapies Study

  2024cites this paper
• Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy

  2024cites this paper
• From standard therapies to monoclonal antibodies and immune checkpoint inhibitors – an update for reconstructive surgeons on common oncological cases

  2024cites this paper
• Personalized therapy in oncology: melanoma as a paradigm for molecular-targeted treatment approaches

  2024cites this paper
• Impact of trametinib on the neuropsychological profile of NF1 patients

  2024cites this paper
• Dabrafenib plus Trametinib: A breakthrough in pediatric low‐grade glioma therapy

  2024cites this paper
• MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma

  2023cites this paper
• Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP

  2023cites this paper
• Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the ‘NSCLC’ of GI Oncology?

  2023cites this paper
• 3D Spheroid Configurations Are Possible Indictors for Evaluating the Pathophysiology of Melanoma Cell Lines

  2023cites this paper
• Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations.

  2023cites this paper
• Cutaneous adverse reactions resulting from targeted cancer therapies: histopathologic and clinical findings.

  2023cites this paper
• Checkpoint kinase 1 inhibitor + low‐dose hydroxyurea efficiently kills BRAF inhibitor‐ and immune checkpoint inhibitor‐resistant melanomas

  2023cites this paper
• Pharmacokinetics/Pharmacodynamics of Dabrafenib and Trametinib for Redifferentiation and Treatment of Radioactive Iodine-Resistant Mutated Advanced Differentiated Thyroid Cancer

  2023cites this paper
• Role of the tumor microenvironment in malignant melanoma organoids during the development and metastasis of tumors

  2023cites this paper
• The Benefits and Challenges of the Multimodal Treatment in Advanced/Metastatic Malignant Melanoma

  2023cites this paper
• TME-targeted approaches of brain metastases and its clinical therapeutic evidence

  2023cites this paper
• Combined Mek inhibition and Pparg activation Eradicates Muscle Invasive Bladder cancer in a Mouse Model of BBN-induced Carcinogenesis

  2023cites this paper
• BRAF L485–P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review

  2023cites this paper
• Diagnosis and Management of Dermatologic Adverse Events from Systemic Melanoma Therapies

  2023cites this paper
• Therapeutic strategies for BRAF mutation in non-small cell lung cancer: a review

  2023cites this paper
• Prognostic factors in diffuse leptomeningeal glioneuronal tumor (DLGNT): a systematic review

  2022cites this paper
• Drug-induced self-assembled nanovesicles for doxorubicin resistance reversal via autophagy inhibition and delivery synchronism

  2022cites this paper
• MELK Promotes Melanoma Growth by Stimulating the NF-kappaB MELK Promotes Melanoma Growth by Stimulating the NF-kappaB Pathway Pathway Let us know how access to this document benefits you.

  2022cites this paper
• Targeted Therapy for Melanomas Without BRAF V600 Mutations

  2022cites this paper
• Nuclear focal adhesion kinase induces APC/C activator protein CDH1-mediated cyclin-dependent kinase 4/6 degradation and inhibits melanoma proliferation

  2022cites this paper
• Proteomic cellular signatures of kinase inhibitor-induced cardiotoxicity

  2022cites this paper
• Treatment of Metastatic Melanoma with a Combination of Immunotherapies and Molecularly Targeted Therapies

  2022cites this paper
• Polymeric scaffolds for antitumor immune cell priming

  2022cites this paper
• Cardiotoxicity Induced by Protein Kinase Inhibitors in Patients with Cancer

  2022cites this paper
• Immunotherapy Options for Acral Melanoma, A fast-growing but Neglected Malignancy.

  2022cites this paper
• BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis

  2022cites this paper
• The MEK Inhibitor Trametinib Improves Outcomes following Subarachnoid Haemorrhage in Female Rats

  2022cites this paper
• Mechanical Properties of the Extracellular Environment of Human Brain Cells Drive the Effectiveness of Drugs in Fighting Central Nervous System Cancers

  2022cites this paper
• Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National Cohort.

  2022cites this paper
• Early experience with targeted therapy as a first-line adjuvant treatment for pediatric low-grade glioma.

  2022cites this paper
• Drugs and the skin: A concise review of cutaneous adverse drug reactions

  2022cites this paper
• Role of dual specificity phosphatases (DUSPs) in melanoma cellular plasticity and drug resistance

  2022cites this paper
• Identification and Characterization of a Novel Dual Inhibitor of Indoleamine 2,3-dioxygenase 1 and Tryptophan 2,3-dioxygenase

  2022cites this paper
• Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma

  2022cites this paper
• Clinical characteristics and treatment outcomes of non-V600 E/K BRAF mutant melanoma patients: a single-institution experience

  2022cites this paper
• Dieckol Inhibits Autophagic Flux and Induces Apoptotic Cell Death in A375 Human Melanoma Cells via Lysosomal Dysfunction and Mitochondrial Membrane Impairment

  2022cites this paper
• [The identification of lung cancer gene-drug module based on multiplex networks algorithm].

  2021cites this paper
• Transdermal Delivery of Chemotherapeutics: Strategies, Requirements, and Opportunities

  2021cites this paper
• Dabrafenib and Trametinib

  2021cites this paper
• Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition

  2021cites this paper
• Rapamycin synergizes the cytotoxic effects of MEK inhibitor binimetinib and overcomes acquired resistance to therapy in melanoma cell lines in vitro

  2021cites this paper
• Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical field.

  2021cites this paper
• Diffuse leptomeningeal glioneuronal tumour (DLGNT) in children: the emerging role of genomic analysis

  2021cites this paper
• Nuclear Imaging for the Assessment of Cardiotoxicity from Chemotherapeutic Agents in Oncologic Disease

  2021cites this paper
• Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK

  2021cites this paper
• Adult pilocytic astrocytoma in the molecular era: a comprehensive review

  2021cites this paper
• Advances in anti-BRAF therapies for lung cancer

  2021cites this paper
• Personalized oncology and BRAFK601N melanoma: model development, drug discovery, and clinical correlation

  2021cites this paper
• Carfilzomib in Combination with Bortezomib Enhances Apoptotic Cell Death in B16-F1 Melanoma Cells

  2021cites this paper
• Diverse landscape of dermatologic toxicities from small‐molecule inhibitor cancer therapy

  2021cites this paper
• Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreatic adenocarcinoma

  2020cites this paper
• Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial

  2020cites this paper
• MEK inhibitors in non-V600 BRAF mutations and fusions

  2020cites this paper
• Metastasis to the Central Nervous System.

  2020cites this paper
• Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation

  2020cites this paper
• Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors

  2020cites this paper
• Multikinase inhibitor-induced liver injury in patients with cancer: A review for clinicians.

  2020cites this paper
• Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders.

  2020cites this paper
• Targeted Therapy in BRAF p.K601E-Driven NSCLC: Case Report and Literature Review.

  2020cites this paper
• Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation

  2020cites this paper
• Cutaneous Melanoma – A Review of Systemic Therapies

  2020cites this paper
• A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report

  2020cites this paper
• Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma

  2020cites this paper
• A bilateral optic neuritis side effect of biological treatment with pembrolizumab in a patient with metastatic melanoma

  2020cites this paper
• The MAP kinase signal transduction pathway: promising therapeutic targets used in the treatment of melanoma

  2020cites this paper
• MEK inhibition causes Bim stabilization and sensitivity to Bcl2 family member inhibitors in RAS-MAPK mutated neuroblastoma

  2020cites this paper